Weekly RSV Vaccination Dashboard

Adults 60+ RSV Vaccination Coverage

RSV vaccination coverage estimates among adults 75 years and older and 60─74 years with high-risk conditions for RSV are based on data from CDC's National Immunization Survey─Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Data and charts are available here.

• Additional RSV vaccination data by demographic characteristics at the national and regional level are available.

Adults 75+ RSV Vaccination Administration and Coverage (monthly)

RSV vaccination coverage estimates among adults 75 years and older as of the end of December 2024 based on IIS data submitted to CDC by 39 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available here.

Adults 75+ RSV Vaccination Coverage (monthly)

RSV vaccination coverage among Medicare fee-for-service beneficiaries 75 years and older and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services. Data and charts are available here.

RSV Vaccinations Administered in Pharmacies and Medical Offices (IQVIA)

IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians' medical offices for adults 60 years and older, based on healthcare claims data. Data and charts are available here.

Pregnant Women RSV Vaccination Coverage

Estimates of RSV vaccination coverage for pregnant women 18─49 years are calculated using data from CDC's Vaccine Safety Datalink (VSD). VSD data includes electronic health records data from ten integrated health systems. Data and charts are available here.

Nirsevimab Coverage and Intent for Infants (monthly)

Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of nirsevimab, as well as intent for nirsevimab receipt, reported by females age 18─49 years with infants <8 months during the RSV season (born since April 1, 2024) are based on data from CDC’s National Immunization Survey─Adult COVID Module. Estimates of nirsevimab coverage and intent are based on respondent self-report. Data and charts are available here.

Nirsevimab Administration and Coverage for Infants (monthly)

Nirsevimab administration and coverage estimates among infants <8 months (born since April 1, 2024) as of the end of December 2024 based on IIS data submitted to CDC by 39 immunization awardee jurisdictions. The coverage of some Pacific Island jurisdictions may reflect vaccination program activities aligned with regional virus circulation patterns (i.e., they may vaccinate on a different schedule than the continental U.S.). Data and charts are available here.